Andreia Miranda

Andreia Miranda

Auto-generated profile, based on publicly available information

Andreia Miranda

Experimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
APAndreia Peixoto
Andreia Peixoto
DFDylan Ferreira
Dylan Ferreira
AMAndreia Miranda
Andreia Miranda
MRMarta Relvas-Santos
Marta Relvas-Santos
RFRui Freitas
Rui Freitas
José Alexandre FerreiraJosé Alexandre Ferreira
José Alexandre Ferreira
Bladder tumours with aggressive characteristics often present with microenvironmental niches marked by low oxygen levels (hypoxia) and limited glucose supply due to inadequate vascularization. The molecular mechanisms facilitating cellular adaptation to these stimuli remain largely elusive. Employing a multi-omics approach, we discovered that hypoxic and glucose- deprived cancer cells enter a quiescent state supported by mitophagy, fatty acid β -oxidation, and amino acid catabolism, concurrently enhancing their invasive capabilities. Reoxygenation and glucose restoration efficiently reversed cell quiescence without affecting cellular viability, highlighting significant molecular plasticity in adapting to microenvironmental challenges. Furthermore, cancer cells exhibited substantial perturbation of protein O -glycosylation, leading to simplified glycophenotypes with shorter glycosidic chains. Exploiting glycoengineered cell models, we established that immature glycosylation contributes to reduced cell proliferation and increased invasion. Our findings collectively indicate that hypoxia and glucose deprivation trigger cancer aggressiveness, reflecting an adaptive escape mechanism underpinned by altered metabolism and protein glycosylation, providing grounds for clinical intervention.

15 May 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
AMAndreia Miranda
Andreia Miranda
MRMarta Relvas-Santos
Marta Relvas-Santos
CLCamila Lourenço
Camila Lourenço
EFEduardo Ferreira
Eduardo Ferreira
DCDiogo M. Cunha
Diogo M. Cunha
José Alexandre FerreiraJosé Alexandre Ferreira
José Alexandre Ferreira
Immature protein O-glycosylation, characterized by the Tn antigen expression rather than complex glycans, is prevalent in advanced solid tumors and promotes immune evasion. We developed GlycoAvatars, magnetic beads coated with plasma-membrane glycoproteins from glycoengineered cancer cells reflecting these alterations, to identify cancer-immune cell interactomes. We uncovered numerous membrane and intracellular proteins involved in glycan-mediated immune signaling, providing a novel high-throughput strategy for identifying potential relevant molecular nodes foreseeing therapeutic targets.

15 November 2013
Verified
Book Chapter
Closed access
PDF file
JMJairo Martins
Jairo Martins
MRMarcia Ramos
Marcia Ramos
AMA.C.T Miranda
A.C.T Miranda
LDL.A.G. Dimache
L.A.G. Dimache
ASA.T. Silva
A.T. Silva
FAFernando Queiroz de Almeida
Fernando Queiroz de Almeida
"Urinary parameters in horses supplemented with pulse dose of electrolytes" published on 15 Nov 2013 by Wageningen Academic.

18 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAndreia Miranda
Andreia Miranda
MRMarta Relvas-Santos
Marta Relvas-Santos
CLCamila Lourenço
Camila Lourenço
EFEduardo Ferreira
Eduardo Ferreira
DCDiogo M. Cunha
Diogo M. Cunha
José Alexandre FerreiraJosé Alexandre Ferreira
José Alexandre Ferreira
Immature O -glycosylation of plasma membrane proteins, characterized by the presence of glycosites with a single GalNAc residue (the Tn antigen) rather than more extended and complex glycans, is a prominent feature of many advanced solid tumors across different origins and aetiologies. This form of glycosylation has been strongly associated with poor prognosis and is known to play a crucial role in the progression of the disease. Notably, it has been directly implicated in the crosstalk with the immune system, inducing tolerogenic phenotypes in both innate and adaptive immune cells. Despite this, the specific receptors involved in these interactions remain largely unidentified. To address this gap, we propose a novel high-throughput proteomics assisted strategy for characterizing the glycan interactome using plasma membrane-derived glycoprotein coated magnetic beads. Glycoproteins were isolated from plasma membranes of glycoengineered cell models with immature glycosylation and were then cloaked on the surface of magnetic beads, creating simplified cell “GlycoAvatars.” These GlycoAvatars were primarily employed to characterize the interactome between gastric and colorectal cancer cell lines and immune cells (dendritic cells and macrophages), providing a tool for identifying potentially relevant molecular nodes in glycan-mediated immune synapses, foreseeing their application in deciphering tumor-immune interactions.

2 August 2025 in bioRxiv
Verified
Preprint
Open access
ESEliana Soares
Eliana Soares
DFDylan Ferreira
Dylan Ferreira
AMAndreia Miranda
Andreia Miranda
MGMartina Gonçalves
Martina Gonçalves
MRMarta Relvas-Santos
Marta Relvas-Santos
José Alexandre FerreiraJosé Alexandre Ferreira
José Alexandre Ferreira
Colorectal cancer (CRC) progression is fueled by immune evasion, yet the underlying molecular mechanisms remain to be fully characterized. CD276 (B7-H3), an immune checkpoint glycoprotein frequently overexpressed in aggressive tumours, is extensively modified by glycosylation, a process known to regulate protein stability, localization, and immune interactions. However, its glycosylation-dependent functions in CRC remain unclear. This study shows that poor-prognosis CRC tumours exhibit dysregulated glycogene expression, leading to an immature O -glycosylation phenotype that enhances malignancy. Using C1GALT1 knockout CRC cells, which recapitulate the cancer glycocalyx, it was demonstrated that this glycosylation shift promotes proliferation and invasion. We further identify CD276 as a metastasis-associated glycoprotein whose function is shaped by O -glycan modifications. Mechanistically, immature O -glycosylation of CD276 enhances invasion, suppresses T-cell activation, and induces an immunosuppressive cytokine milieu, reinforcing its role in tumour immune escape. These findings establish CD276 as a glycosylation-dependent immune checkpoint and a promising therapeutic target to overcome immune evasion in CRC. Graphical Table of Contents: Colorectal cancer (CRC) progression is closely linked to immune evasion, yet the molecular mechanisms underlying this process remain poorly understood. This study identifies CD276 (B7-H3) as a glycosylation-driven regulator of CRC aggressiveness and demonstrates how O -glycosylation remodeling promotes tumour immune escape. These findings establish CD276 as a potential therapeutic target and highlight the role of glycoproteoform-specific immune modulation in cancer progression.

15 November 2013
Verified
Book Chapter
Closed access
PDF file
JAJ.F. Azevedo
J.F. Azevedo
AMA.C.T. Miranda
A.C.T. Miranda
MRMarcia Ramos
Marcia Ramos
COChiara Oliveira
Chiara Oliveira
FPFelipe Gomes Ferreira Padilha
Felipe Gomes Ferreira Padilha
FAFernando Queiroz de Almeida
Fernando Queiroz de Almeida
"Evaluation of post-exercise recovery in eventing horses" published on 15 Nov 2013 by Wageningen Academic.